Application 209115
- Type
- NDA
- Sponsor
- CLOVIS ONCOLOGY INC
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | RUBRACA | RUCAPARIB CAMSYLATE | TABLET;ORAL | EQ 200MG BASE | Yes | No |
| 002 | RUBRACA | RUCAPARIB CAMSYLATE | TABLET;ORAL | EQ 300MG BASE | Yes | Yes |
| 003 | RUBRACA | RUCAPARIB CAMSYLATE | TABLET;ORAL | EQ 250MG BASE | Yes | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N209115-001 | RUBRACA | RUCAPARIB CAMSYLATE | EQ 200MG BASE | TABLET / ORAL | RLD | 2016-12-19 | |
| N209115-002 | RUBRACA | RUCAPARIB CAMSYLATE | EQ 300MG BASE | TABLET / ORAL | RLD, RS | 2016-12-19 | |
| N209115-003 | RUBRACA | RUCAPARIB CAMSYLATE | EQ 250MG BASE | TABLET / ORAL | RLD | 2017-05-01 |
Orange Book patents#
| Application-product | Patent | Expiration | Use code | Coverage / status | Submission date |
|---|---|---|---|---|---|
| N209115-001 | 8071579 | 2027-08-12 | U-2012 | 2016-12-21 | |
| N209115-001 | 8071579 | 2027-08-12 | U-2273 | 2016-12-21 | |
| N209115-001 | 8071579 | 2027-08-12 | U-2830 | 2016-12-21 | |
| N209115-001 | 8143241 | 2027-08-12 | U-2012 | 2016-12-21 | |
| N209115-001 | 8143241 | 2027-08-12 | U-2273 | 2016-12-21 | |
| N209115-001 | 8143241 | 2027-08-12 | U-2830 | 2016-12-21 | |
| N209115-001 | 10278974 | 2031-02-10 | Drug product | 2019-06-04 | |
| N209115-001 | 8754072 | 2031-02-10 | Drug substance, Drug product | 2016-12-21 | |
| N209115-001 | 9045487 | 2031-02-10 | Drug substance, Drug product | 2016-12-21 | |
| N209115-001 | 9861638 | 2031-02-10 | U-2012 | 2018-02-06 | |
| N209115-001 | 9861638 | 2031-02-10 | U-2273 | 2018-02-06 | |
| N209115-001 | 8859562 | 2031-08-04 | U-2012 | 2016-12-21 | |
| N209115-001 | 8859562 | 2031-08-04 | U-2273 | 2016-12-21 | |
| N209115-001 | 8859562 | 2031-08-04 | U-2830 | 2016-12-21 | |
| N209115-001 | 10130636 | 2035-08-17 | U-2012 | 2018-12-17 | |
| N209115-001 | 10130636 | 2035-08-17 | U-2101 | 2018-12-17 | |
| N209115-001 | 10130636 | 2035-08-17 | U-2273 | 2018-12-17 | |
| N209115-001 | 10130636 | 2035-08-17 | U-2830 | 2018-12-17 | |
| N209115-001 | 9987285 | 2035-08-17 | Drug product | 2018-06-28 | |
| N209115-002 | 8071579 | 2027-08-12 | U-2012 | 2016-12-21 | |
| N209115-002 | 8071579 | 2027-08-12 | U-2273 | 2016-12-21 | |
| N209115-002 | 8071579 | 2027-08-12 | U-2830 | 2016-12-21 | |
| N209115-002 | 8143241 | 2027-08-12 | U-2012 | 2016-12-21 | |
| N209115-002 | 8143241 | 2027-08-12 | U-2273 | 2016-12-21 | |
| N209115-002 | 8143241 | 2027-08-12 | U-2830 | 2016-12-21 | |
| N209115-002 | 10278974 | 2031-02-10 | Drug product | 2019-06-04 | |
| N209115-002 | 8754072 | 2031-02-10 | Drug substance, Drug product | 2016-12-21 | |
| N209115-002 | 9045487 | 2031-02-10 | Drug substance, Drug product | 2016-12-21 | |
| N209115-002 | 9861638 | 2031-02-10 | U-2012 | 2018-02-06 | |
| N209115-002 | 9861638 | 2031-02-10 | U-2273 | 2018-02-06 | |
| N209115-002 | 8859562 | 2031-08-04 | U-2012 | 2016-12-21 | |
| N209115-002 | 8859562 | 2031-08-04 | U-2273 | 2016-12-21 | |
| N209115-002 | 8859562 | 2031-08-04 | U-2830 | 2016-12-21 | |
| N209115-002 | 10130636 | 2035-08-17 | U-2012 | 2018-12-17 | |
| N209115-002 | 10130636 | 2035-08-17 | U-2101 | 2018-12-17 | |
| N209115-002 | 10130636 | 2035-08-17 | U-2273 | 2018-12-17 | |
| N209115-002 | 10130636 | 2035-08-17 | U-2830 | 2018-12-17 | |
| N209115-002 | 9987285 | 2035-08-17 | Drug product | 2018-06-28 | |
| N209115-003 | 8071579 | 2027-08-12 | U-2012 | 2017-05-09 | |
| N209115-003 | 8071579 | 2027-08-12 | U-2273 | 2017-05-09 | |
| N209115-003 | 8071579 | 2027-08-12 | U-2830 | 2017-05-09 | |
| N209115-003 | 8143241 | 2027-08-12 | U-2012 | 2017-05-09 | |
| N209115-003 | 8143241 | 2027-08-12 | U-2273 | 2017-05-09 | |
| N209115-003 | 8143241 | 2027-08-12 | U-2830 | 2017-05-09 | |
| N209115-003 | 10278974 | 2031-02-10 | Drug product | 2019-06-04 | |
| N209115-003 | 8754072 | 2031-02-10 | Drug substance, Drug product | 2017-05-09 | |
| N209115-003 | 9045487 | 2031-02-10 | Drug substance, Drug product | 2017-05-09 | |
| N209115-003 | 9861638 | 2031-02-10 | U-2012 | 2018-02-06 | |
| N209115-003 | 9861638 | 2031-02-10 | U-2273 | 2018-02-06 | |
| N209115-003 | 8859562 | 2031-08-04 | U-2012 | 2017-05-09 | |
| N209115-003 | 8859562 | 2031-08-04 | U-2273 | 2017-05-09 | |
| N209115-003 | 8859562 | 2031-08-04 | U-2830 | 2017-05-09 | |
| N209115-003 | 10130636 | 2035-08-17 | U-2012 | 2018-12-17 | |
| N209115-003 | 10130636 | 2035-08-17 | U-2101 | 2018-12-17 | |
| N209115-003 | 10130636 | 2035-08-17 | U-2273 | 2018-12-17 | |
| N209115-003 | 10130636 | 2035-08-17 | U-2830 | 2018-12-17 | |
| N209115-003 | 9987285 | 2035-08-17 | Drug product | 2018-06-28 |
Orange Book exclusivity#
| Application-product | Exclusivity code | Expiration |
|---|---|---|
| N209115-001 | I-982 | 2028-12-17 |
| N209115-002 | I-982 | 2028-12-17 |
| N209115-003 | I-982 | 2028-12-17 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | N209115-001 | RUBRACA | EQ 200MG BASE | TABLET / ORAL | RLD | 2016-12-19 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-002 | RUBRACA | EQ 300MG BASE | TABLET / ORAL | RLD, RS | 2016-12-19 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-003 | RUBRACA | EQ 250MG BASE | TABLET / ORAL | RLD | 2017-05-01 | a50c72e98297… |
Observed Orange Book patent history#
| Captured | Edition | Application-product | Patent | Expiration | Use code | Coverage / status | Submission date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | N209115-001 | 8071579 | 2027-08-12 | U-2273 | 2016-12-21 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-001 | 8071579 | 2027-08-12 | U-2012 | 2016-12-21 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-001 | 8071579 | 2027-08-12 | U-2830 | 2016-12-21 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-001 | 8143241 | 2027-08-12 | U-2012 | 2016-12-21 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-001 | 8143241 | 2027-08-12 | U-2273 | 2016-12-21 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-001 | 8143241 | 2027-08-12 | U-2830 | 2016-12-21 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-001 | 10278974 | 2031-02-10 | Drug product | 2019-06-04 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-001 | 8754072 | 2031-02-10 | Drug substance, Drug product | 2016-12-21 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-001 | 9045487 | 2031-02-10 | Drug substance, Drug product | 2016-12-21 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-001 | 9861638 | 2031-02-10 | U-2012 | 2018-02-06 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-001 | 9861638 | 2031-02-10 | U-2273 | 2018-02-06 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-001 | 8859562 | 2031-08-04 | U-2012 | 2016-12-21 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-001 | 8859562 | 2031-08-04 | U-2273 | 2016-12-21 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-001 | 8859562 | 2031-08-04 | U-2830 | 2016-12-21 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-001 | 10130636 | 2035-08-17 | U-2273 | 2018-12-17 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-001 | 10130636 | 2035-08-17 | U-2101 | 2018-12-17 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-001 | 10130636 | 2035-08-17 | U-2012 | 2018-12-17 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-001 | 10130636 | 2035-08-17 | U-2830 | 2018-12-17 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-001 | 9987285 | 2035-08-17 | Drug product | 2018-06-28 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-002 | 8071579 | 2027-08-12 | U-2273 | 2016-12-21 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-002 | 8071579 | 2027-08-12 | U-2012 | 2016-12-21 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-002 | 8071579 | 2027-08-12 | U-2830 | 2016-12-21 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-002 | 8143241 | 2027-08-12 | U-2012 | 2016-12-21 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-002 | 8143241 | 2027-08-12 | U-2273 | 2016-12-21 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-002 | 8143241 | 2027-08-12 | U-2830 | 2016-12-21 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-002 | 10278974 | 2031-02-10 | Drug product | 2019-06-04 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-002 | 8754072 | 2031-02-10 | Drug substance, Drug product | 2016-12-21 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-002 | 9045487 | 2031-02-10 | Drug substance, Drug product | 2016-12-21 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-002 | 9861638 | 2031-02-10 | U-2012 | 2018-02-06 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-002 | 9861638 | 2031-02-10 | U-2273 | 2018-02-06 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-002 | 8859562 | 2031-08-04 | U-2273 | 2016-12-21 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-002 | 8859562 | 2031-08-04 | U-2012 | 2016-12-21 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-002 | 8859562 | 2031-08-04 | U-2830 | 2016-12-21 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-002 | 10130636 | 2035-08-17 | U-2101 | 2018-12-17 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-002 | 10130636 | 2035-08-17 | U-2273 | 2018-12-17 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-002 | 10130636 | 2035-08-17 | U-2012 | 2018-12-17 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-002 | 10130636 | 2035-08-17 | U-2830 | 2018-12-17 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-002 | 9987285 | 2035-08-17 | Drug product | 2018-06-28 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-003 | 8071579 | 2027-08-12 | U-2012 | 2017-05-09 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-003 | 8071579 | 2027-08-12 | U-2273 | 2017-05-09 | a50c72e98297… |
Observed Orange Book exclusivity history#
| Captured | Edition | Application-product | Exclusivity code | Expiration | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | N209115-001 | I-982 | 2028-12-17 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N209115-002 | I-982 | 2028-12-17 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N209115-003 | I-982 | 2028-12-17 | a50c72e98297… |
openFDA label cross-check#
Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Rubraca | RUCAPARIB | pharmaand GmbH | 0295d202-1cfe-7659-e063-6294a90a476e | 2025-12-31 | Warnings, Adverse reactions | 209115 NDA209115 |
NDC Listings For This Application#
| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|---|---|---|---|---|
| 69660-201 | Rubraca | rucaparib | Clovis Oncology, Inc. | NDA | Current |
| 69660-201 | Rubraca | rucaparib | Clovis Oncology, Inc. | NDA | Current |
| 69660-201 | Rubraca | rucaparib | Clovis Oncology, Inc. | NDA | Current |
| 69660-201 | Rubraca | rucaparib | Clovis Oncology, Inc. | NDA | Current |
| 69660-201 | Rubraca | rucaparib | Clovis Oncology, Inc. | NDA | Current |
| 69660-201 | Rubraca | rucaparib | Clovis Oncology, Inc. | NDA | Current |
| 69660-202 | Rubraca | rucaparib | Clovis Oncology, Inc. | NDA | Current |
| 69660-202 | Rubraca | rucaparib | Clovis Oncology, Inc. | NDA | Current |
| 69660-202 | Rubraca | rucaparib | Clovis Oncology, Inc. | NDA | Current |
| 69660-202 | Rubraca | rucaparib | Clovis Oncology, Inc. | NDA | Current |
| 69660-202 | Rubraca | rucaparib | Clovis Oncology, Inc. | NDA | Current |
| 69660-202 | Rubraca | rucaparib | Clovis Oncology, Inc. | NDA | Current |
| 69660-203 | Rubraca | rucaparib | Clovis Oncology, Inc. | NDA | Current |
| 69660-203 | Rubraca | rucaparib | Clovis Oncology, Inc. | NDA | Current |
| 69660-203 | Rubraca | rucaparib | Clovis Oncology, Inc. | NDA | Current |
| 69660-203 | Rubraca | rucaparib | Clovis Oncology, Inc. | NDA | Current |
| 69660-203 | Rubraca | rucaparib | Clovis Oncology, Inc. | NDA | Current |
| 69660-203 | Rubraca | rucaparib | Clovis Oncology, Inc. | NDA | Current |
Documents#
| Document | Submission type | Date |
|---|---|---|
| 84484 | SUPPL | 2025-12-22 |
| 84483 | SUPPL | 2025-12-22 |
| 84469 | SUPPL | 2025-12-19 |
| 84468 | SUPPL | 2025-12-19 |
| 73010 | SUPPL | 2022-12-23 |
| 72997 | SUPPL | 2022-12-22 |
| 71270 | SUPPL | 2022-06-13 |
| 71269 | SUPPL | 2022-06-13 |
| 68868 | SUPPL | 2021-10-04 |
| 68856 | SUPPL | 2021-10-01 |
| 64904 | SUPPL | 2020-10-14 |
| 64885 | SUPPL | 2020-10-09 |
| 63092 | SUPPL | 2020-05-19 |
| 63052 | SUPPL | 2020-05-15 |
| 53658 | SUPPL | 2018-04-12 |
| 53633 | SUPPL | 2018-04-06 |
| 47024 | ORIG | 2017-01-30 |
| 46445 | ORIG | 2016-12-21 |
| 46206 | ORIG | 2016-12-19 |